Neil S. Belloff - 30 Jul 2021 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc.

Role: COO, GENERAL COUNSEL &CORP SEC
Signature: /s/ Neil S. Belloff
Issuer symbol: N/A
Transactions as of: 30 Jul 2021
Net transactions value: -$606
Form type: 4
Filing time: 30 Jul 2021, 20:32:44 UTC
Previous filing: 26 May 2021
Next filing: 09 Nov 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ELOX	Common Stock	Options Exercise	$0	+1,563	+4.9%	$0.000000	33,158	30 Jul 2021	Direct	F1
transaction	ELOX	Common Stock	Tax liability	$606	-459	-1.4%	$1.32	32,699	30 Jul 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELOX	Restricted Stock Units	Options Exercise	$0	-1,563	-14%	$0.000000	9,375	30 Jul 2021	Common Stock	1,563		Direct	F1, F2, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The restricted stock units issued to the reporting person onJanuary 30, 2019 have partially vested and settled for shares of the Issuer's common stock.
F2	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3	The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan.
F4	The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated with certain qualifying terminations of service or in connection with a corporate transaction.